Allyson J. Ocean

7.5k citations

81 papers · 1.9k indexed · h-index 18

Impact in

Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Oncology 60
- Pancreatic and Hepatic Oncology Research 20
- HER2/EGFR in Cancer Research 15
- Colorectal Cancer Treatments and Studies 14
- Cancer Treatment and Pharmacology 13
- Cancer Cells and Metastasis 7
- Cancer Immunotherapy and Biomarkers 7
Biotechnology 9
- Cancer Research and Treatments 9

Co-authors: Karen-Sue Carlson David M. Goldenberg Robert M. Sharkey Serengulam V. Govindan Michael J. Guarino William A. Wegener Pius Maliakal Alexander Starodub
Journals: Journal of Clinical Oncology (42 papers)Cancer Research (7 papers)Annals of Oncology (5 papers)Molecular Cancer Therapeutics (2 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Canada Australia

In The Last Decade

Allyson J. Ocean

79 papers receiving 1.9k citations

Peers

Countries citing papers authored by Allyson J. Ocean

Since Specialization

Citations

This map shows the geographic impact of Allyson J. Ocean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allyson J. Ocean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allyson J. Ocean more than expected).

Fields of papers citing papers by Allyson J. Ocean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allyson J. Ocean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allyson J. Ocean. The network helps show where Allyson J. Ocean may publish in the future.

Co-authors

The 25 scholars most cited alongside Allyson J. Ocean, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Allyson J. Ocean Line = papers co-authored together Allyson J. Ocean links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	8MO Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial Annals of Oncology ·P.M. Kasi, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uzma Khan, Alana Nguyen, Despina Siolas, Brandon Swed, Sahrish Khan, M L Wood, Allyson J. Ocean, E Popa, Kelly A. Garrett, E.B. Golden, Preethi Guniganti, Xi Kathy Zhou, Alessio Pigazzi, Manish A. Shah, Erika Hissong, M. Hidalgo	2024	4
2	Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy. Journal of Clinical Oncology ·Paul E. Oberstein, Andrea Wang‐Gillam, Anna M. Varghese, Andrew H. Ko, Andrew Hendifar, Allyson J. Ocean, Anna McGlothlin, Todd Graves, Scott Berry, Michelle A. Detry, Mark Fitzgerald, Anna Bosse, Cassadie Moravek, Kelly A. Feehan, Carrie Meghann Howland, Donald A. Berry, Diane M. Simeone, Vincent J. Picozzi	2024	0
3	Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes Journal of Thrombosis and Haemostasis ·Babak B. Navi, Cenai Zhang, Carla Sherman, Richard Genova, Natalie M. LeMoss, Hooman Kamel, Scott T. Tagawa, Ashish Saxena, Allyson J. Ocean, Scott E. Kasner, Mary Cushman, Mitchell S.V. Elkind, Ellinor I.B. Peerschke, Lisa M. DeAngelis	2022	22
4	A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond Cancer Medicine ·Marcus Smith Noel, Semmie Kim, Marion L. Hartley, Steve Wong, Vincent J. Picozzi, Harry Staszewski, Dae Won Kim, Jan M. Van Tornout, Philip Agop Philip, Vincent Chung, Allyson J. Ocean, Andrea Wang‐Gillam	2022	6
5	Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis JMIR Cancer ·Udhayvir Singh Grewal, Arjun Gupta, Jamie Doggett, Emil Lou, Niraj J. Gusani, Anirban Maitra, Muhammad Shaalan Beg, Allyson J. Ocean	2022	6
6	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage Communications Biology ·Ada Gjyrezi, Giuseppe Galletti, Jiaren Zhang, Daniel Worroll, Michael Sigouros, Seaho Kim, Victoria Cooley, Karla V. Ballman, Allyson J. Ocean, Manish A. Shah, Joseph M. Scandura, Andrea Sboner, David M. Nanus, Himisha Beltran, Scott T. Tagawa, Paraskevi Giannakakou	2021	5
7	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma Investigational New Drugs ·Hani M. Babiker, Peter J. Schlegel, Lee G. Hicks, Andrea J. Bullock, Nafisa Burhani, Daruka Mahadevan, Emad Elquza, Mitesh J. Borad, Ely Benaim, Christine B. Peterson, Callie Heaton, Allyson J. Ocean	2021	4
8	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS -Mutated Colorectal Cancer Molecular Cancer Therapeutics ·Sanjay Goel, Allyson J. Ocean, Ruwan Y. Parakrama, Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, Sengottuvel Viswanathan, Himanshu Kharkwal, Matthew Coffey, Radhashree Maitra	2020	25
9	SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC) Annals of Oncology ·Mary Noel, A. Wang-Gillam, Allyson J. Ocean, Saurabh Chawla, Vincent Chung, G. DelPriore, Vincent J. Picozzi	2019	1
10	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab -Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer SHILAP Revista de lepidopterología ·Vaibhav Sahai, Mohd Saif, Aparna Kalyan, Philip A. Philip, Caio Rocha‐Lima, Allyson J. Ocean, Michael S. Ondovik, Diane M. Simeone, Sibabrata Banerjee, Rafia Bhore, Chrystal U. Louis, Vincent J. Picozzi	2019	11
11	Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan Journal of Clinical Oncology ·Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge	2017	139
12	A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer Annals of Oncology ·Vincent J. Picozzi, Vaibhav Sahai, Diane M. Simeone, Caio Rocha Lima, Allyson J. Ocean, Philip Philip, Wasif M. Saif, Aparna Kalyan, Michael S. Ondovik, Jack Shiansong Li, Chrystal U. Louis	2017	1
13	Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response Clinical Cancer Research ·Bryan J. Schneider, Manish A. Shah, Kelsey Klute, Allyson J. Ocean, E Popa, Nasser K. Altorki, Michael W. Lieberman, Andrew M. Schreiner, Rhonda K. Yantiss, Paul J. Christos, Romae Palmer, Daoqi You, Agnès Viale, Pouneh Kermani, Joseph M. Scandura	2016	51
14	Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis European Journal of Cancer ·Kelsey Klute, Julianna Brouwer, Minaxi Jhawer, Hayley Sachs, Anatasia Gangadin, Allyson J. Ocean, E Popa, Tong Dai, Guojiao Wu, Paul J. Christos, Manish A. Shah	2016	43
15	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Clinical Cancer Research ·Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg	2015	252
16	Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma Clinical Genitourinary Cancer ·Bishoy M. Faltas, David M. Goldenberg, Allyson J. Ocean, Serengulam V. Govindan, François Wilhelm, Robert M. Sharkey, Julio Hajdenberg, Gillian Hodes, David M. Nanus, Scott T. Tagawa	2015	81
17	Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach Investigational New Drugs ·Allyson J. Ocean, Paul J. Christos, Joseph A. Sparano, Manish A. Shah, Rhonda K. Yantiss, Jonathan D. Cheng, Juan Lin, Michael Papetti, Dan Matulich, Felice Schnoll‐Sussman, Christen Besanceney‐Webler, Jenny Xiang, Maureen M. Ward, Kaili Temple Dilts, Roger Keresztes, S. Holloway, Eric X. Chen, James R. Wright, Maureen E. Lane	2014	11
18	Fractionated radioimmunotherapy with ⁹⁰ Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer Cancer ·Allyson J. Ocean, Kenneth Pennington, Michael J. Guarino, Arif Sheikh, Tanios Bekaii‐Saab, Aldo N. Serafini, Daniel Lee, Max W. Sung, Seza Güleç, Stanley J. Goldsmith, Timothy Manzone, Michael Holt, Bert H. O’Neil, Nathan C. Hall, Alberto J. Montero, John Kauh, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg	2012	64
19	Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma American Journal of Clinical Oncology ·Anthony Lam, Joseph A. Sparano, Vincent Vinciguerra, Allyson J. Ocean, Paul J. Christos, Howard S. Höchster, Fernando Camacho, Sanjay Goel, Sridhar Mani, Andreas Kaubisch	2010	36
20	A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma American Journal of Clinical Oncology ·Rachel Raab, Joseph A. Sparano, Allyson J. Ocean, Paul J. Christos, Mark Ramirez, Vincent Vinciguerra, Andreas Kaubisch	2010	13

About Allyson J. Ocean

Allyson J. Ocean is a scholar working on Oncology, Biotechnology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 81 papers that have together received 1.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (20 papers), HER2/EGFR in Cancer Research (15 papers), Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (13 papers), Radiopharmaceutical Chemistry and Applications (13 papers), Cancer Research and Treatments (9 papers), Cancer Cells and Metastasis (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Hepatology (335 citations), Oncology (1.1k citations), Radiology, Nuclear Medicine and Imaging (361 citations), Pulmonary and Respiratory Medicine (496 citations) and Cancer Research (205 citations). Allyson J. Ocean has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Karen-Sue Carlson, David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan, Michael J. Guarino, William A. Wegener, Pius Maliakal, Alexander Starodub, Manish A. Shah and Paul J. Christos. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Molecular Cancer Therapeutics and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact